Tech Company Financing Transactions
Actithera Funding Round
On 7/9/2025, Actithera announced $75.5 million in Series A funding from 4BIO Capital, Hadean Ventures and M Ventures.
Transaction Overview
Company Name
Announced On
7/9/2025
Transaction Type
Venture Equity
Amount
$75,500,000
Round
Series A
Investors
4BIO Capital (Lead Investor)
Hadean Ventures (Lead Investor)
M Ventures (Lead Investor)
Sofinnova Partners (Lead Investor)
Proceeds Purpose
The company intends to use the funds to support the advancement of its lead FAP asset into clinical development in multiple indications, while also enabling the continued development of its proprietary RLT discovery platform and preclinical pipeline.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1 Broadway, 14th Floor
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Website
Email Address
Overview
Actithera is dedicated to developing precisely targeted radioligand therapies to serve cancer patients with high unmet medical needs. Actithera leverages proprietary chemistries to design best-in-class radioligand therapies that persist in tumors while sparing healthy tissues. We are driven by a collaborative and empowering culture where talented individuals come together with a shared mission: to transform the lives of cancer patients through innovative science.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Andreas Goutopoulos
Browse more venture capital transactions:
Prev: 7/9/2025: Moment venture capital transaction
Next: 7/9/2025: ZeroEntropy venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC transactions reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs